AdvaMed Plays Tariff Chess, Trump Plays Checkers
As tariff uncertainty continues in 2025, AdvaMed plays tariff chess, advocating for predictable, zero-for-zero policies to protect medtech innovation and access.
AdvaMed Advancements
AdvaMed® Advancements: Q4 2025 Report
AdvaMed® Advancements: Q4 2025 Report highlights how unified industry advocacy responded to policy disruption, trade uncertainty, and federal action impacting medtech.
AdvaMed® Advancements: Q3 2025 Report
AdvaMed® Advancements: Q3 2025 Report. Amid an increasingly charged political environment, AdvaMed remained a steady, persuasive voice for medtech innovation. From mobilizing rapid action on the Section 232 investigation to…
AdvaMed® Advancements: Q2 2025 Report
Discover our Q2 report highlighting key industry wins, tariff updates, and strategic progress driving medtech innovation and advocacy forward.
2024 Annual Report
Explore AdvaMed®’s key achievements and milestones in 2024 on behalf of our member companies and the patients they serve.
AdvaMed® Advancements: Q3 2024 Report
AdvaMed® Advancements: Q3 2024 Report is proud to showcase the significant achievements we accomplished in Q3 of 2024.